147 related articles for article (PubMed ID: 24412476)
1. Cytokine release assays: current practices and future directions.
Finco D; Grimaldi C; Fort M; Walker M; Kiessling A; Wolf B; Salcedo T; Faggioni R; Schneider A; Ibraghimov A; Scesney S; Serna D; Prell R; Stebbings R; Narayanan PK
Cytokine; 2014 Apr; 66(2):143-55. PubMed ID: 24412476
[TBL] [Abstract][Full Text] [Related]
2. Cytokine release: A workshop proceedings on the state-of-the-science, current challenges and future directions.
Grimaldi C; Finco D; Fort MM; Gliddon D; Harper K; Helms WS; Mitchell JA; O'Lone R; Parish ST; Piche MS; Reed DM; Reichmann G; Ryan PC; Stebbings R; Walker M
Cytokine; 2016 Sep; 85():101-8. PubMed ID: 27309676
[TBL] [Abstract][Full Text] [Related]
3. A whole blood in vitro cytokine release assay with aqueous monoclonal antibody presentation for the prediction of therapeutic protein induced cytokine release syndrome in humans.
Wolf B; Morgan H; Krieg J; Gani Z; Milicov A; Warncke M; Brennan F; Jones S; Sims J; Kiessling A
Cytokine; 2012 Dec; 60(3):828-37. PubMed ID: 22986013
[TBL] [Abstract][Full Text] [Related]
4. Development of a human whole blood assay for prediction of cytokine release similar to anti-CD28 superagonists using multiplex cytokine and hierarchical cluster analysis.
Walker MR; Makropoulos DA; Achuthanandam R; Van Arsdell S; Bugelski PJ
Int Immunopharmacol; 2011 Nov; 11(11):1697-705. PubMed ID: 21689786
[TBL] [Abstract][Full Text] [Related]
5. Development of the first reference antibody panel for qualification and validation of cytokine release assay platforms - Report of an international collaborative study.
Vessillier S; Fort M; O'Donnell L; Hinton H; Nadwodny K; Piccotti J; Rigsby P; Staflin K; Stebbings R; Mekala D; Willingham A; Wolf B;
Cytokine X; 2020 Dec; 2(4):100042. PubMed ID: 33458650
[TBL] [Abstract][Full Text] [Related]
6. Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm.
Vessillier S; Eastwood D; Fox B; Sathish J; Sethu S; Dougall T; Thorpe SJ; Thorpe R; Stebbings R
J Immunol Methods; 2015 Sep; 424():43-52. PubMed ID: 25960173
[TBL] [Abstract][Full Text] [Related]
7. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.
Suntharalingam G; Perry MR; Ward S; Brett SJ; Castello-Cortes A; Brunner MD; Panoskaltsis N
N Engl J Med; 2006 Sep; 355(10):1018-28. PubMed ID: 16908486
[TBL] [Abstract][Full Text] [Related]
8. Cytokine storm and an anti-CD28 monoclonal antibody.
Gardner K
N Engl J Med; 2006 Dec; 355(24):2591-2; author reply 2593-4. PubMed ID: 17171819
[No Abstract] [Full Text] [Related]
9. Cytokine storm and an anti-CD28 monoclonal antibody.
Garcia-Bournissen F; Boragina M; Ito S
N Engl J Med; 2006 Dec; 355(24):2593; author reply 2593-4. PubMed ID: 17167937
[No Abstract] [Full Text] [Related]
10. Cytokine storm and an anti-CD28 monoclonal antibody.
Takita M; Matsumura T; Kami M
N Engl J Med; 2006 Dec; 355(24):2593; author reply 2593-4. PubMed ID: 17171821
[No Abstract] [Full Text] [Related]
11. Cytokine storm and an anti-CD28 monoclonal antibody.
Puellmann K; Beham AW; Kaminski WE
N Engl J Med; 2006 Dec; 355(24):2592-3; author reply 2593-4. PubMed ID: 17167145
[No Abstract] [Full Text] [Related]
12. Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08.
Tabares P; Berr S; Römer PS; Chuvpilo S; Matskevich AA; Tyrsin D; Fedotov Y; Einsele H; Tony HP; Hünig T
Eur J Immunol; 2014 Apr; 44(4):1225-36. PubMed ID: 24374661
[TBL] [Abstract][Full Text] [Related]
13. Cytokine storm and an anti-CD28 monoclonal antibody.
Corry DB; Lewis DE
N Engl J Med; 2006 Dec; 355(24):2592; author reply 2593-4. PubMed ID: 17171820
[No Abstract] [Full Text] [Related]
14. A predictive biomimetic model of cytokine release induced by TGN1412 and other therapeutic monoclonal antibodies.
Dhir V; Fort M; Mahmood A; Higbee R; Warren W; Narayanan P; Wittman V
J Immunotoxicol; 2012; 9(1):34-42. PubMed ID: 22074378
[TBL] [Abstract][Full Text] [Related]
15. After TGN1412: recent developments in cytokine release assays.
Stebbings R; Eastwood D; Poole S; Thorpe R
J Immunotoxicol; 2013; 10(1):75-82. PubMed ID: 22967038
[TBL] [Abstract][Full Text] [Related]
16. Survey: immune function and immunotoxicity assessment in dogs.
Lebrec H; O'Lone R; Freebern W; Komocsar W; Moore P
J Immunotoxicol; 2012; 9(1):1-14. PubMed ID: 22059464
[TBL] [Abstract][Full Text] [Related]
17. Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety.
MacLeod E; Rajagopal D; Vessillier S
J Vis Exp; 2023 Sep; (199):. PubMed ID: 37782084
[TBL] [Abstract][Full Text] [Related]
18. Summary of a workshop on nonclinical and clinical immunotoxicity assessment of immunomodulatory drugs.
Piccotti JR; Lebrec HN; Evans E; Herzyk DJ; Hastings KL; Burns-Naas LA; Gourley IS; Wierda D; Kawabata TT
J Immunotoxicol; 2009 Mar; 6(1):1-10. PubMed ID: 19519157
[TBL] [Abstract][Full Text] [Related]
19. The rise and fall of the CD28 superagonist TGN1412 and its return as TAB08: a personal account.
Hünig T
FEBS J; 2016 Sep; 283(18):3325-34. PubMed ID: 27191544
[TBL] [Abstract][Full Text] [Related]
20. Challenges and gaps in immunosafety evaluation of therapeutics: An IQ DruSafe survey.
Collinge M; Neff-LaFord H; Akella S; Fogal B; Fraser K; Jabbour J; Harper K; Maier CC; Malherbe L; Marshall N; Rao GK; Raman K; Skaggs H; Weber F; Fuller CL
Regul Toxicol Pharmacol; 2024 Jun; 150():105630. PubMed ID: 38642729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
